[Aggressive lymphoma (DLBCL, MCL) - what's new?]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Context:

• Significant progress in understanding lymphoma molecular basis, including genetic alterations like TP53 mutations in MCL.
• Identification of genetic markers with prognostic impact on disease course.

Purpose:

• To summarize recent findings in tumor biology and therapeutic developments for Diffuse Large B-cell Lymphoma (DLBCL) and MCL.
• To highlight the need for optimized, individualized strategies for high-risk lymphoma patients.

Summary:

• Deepened molecular insights facilitate rapid development of targeted and immuno-based therapies.
• New therapies are increasingly used in first-line treatments for DLBCL and MCL, potentially replacing conventional chemotherapy.
• Despite advances, primary refractory disease and early relapses show moderate responses and limited survival.

Impact:

• Potential for individualized, risk-adapted treatment strategies to improve patient care.
• Highlights the unmet need for advanced therapeutic options for refractory and relapsed lymphoma patients.
• Expands the therapeutic landscape for DLBCL and MCL by integrating novel findings in tumor biology.